Lenvima – pharmaceutical daily

May 29, 2020 Off

KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma

Analyses from KEYTRUDA Plus LENVIMA Trials to be Presented at 2020 ASCO Annual Meeting KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.–(BUSINESS…

September 29, 2019 Off

Merck, Eisai welcome final study results for Keytruda/Lenvima combo treatment in advanced endometrial cancer presented at ESMO 2019 congress

By BusinessWire

“The results of this Keytruda plus Lenvima study are a welcome development in the treatment of women with advanced endometrial cancer, a patient group with an unmet medical need,” said Dr. Vicky Makker, principal investigator and medical oncologist, Memorial Sloan Kettering Cancer Center.

September 18, 2019 Off

FDA Approves Keytruda/Lenvima combination treatment for certain types of endometrial carcinoma

By BusinessWire

Keytruda/lenvima combination treatment has been approved for certain patients with advanced endometrial carcinoma which isn’t Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR)